Neovasc's Tiara TMVR enjoys success in new study

A small study of the Neovasc (NSDQ:NVCN) Tiara transcatheter mitral valve replacement (TMVR) in high-risk patients revealed a 100% procedural success rate and immediate elimination of mitral regurgitation.

Neovasc Tiara, prosthetic tissue mitral valve

Published in Circulation: Cardiovascular Interventions, the study also showed no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days.

The twelve patients in the study had had a previous aortic valve replacement. Such patients have been excluded from most TMVR trials because of the potential risks of left ventricular outflow tract obstruction or interaction between the TMVR anchoring mechanism and the aortic prosthesis, according to the study.

Full story at Mass Device:


A Zone Portfolio Company

Gulf Canada Square
Suite 1000, 401 - 9th Avenue SW

Calgary, Alberta

Canada T2P 3C5

©2018 by Advancare Medical Technologies Inc.